BioLineRx Ltd. Receives Approval To Commence Phase 1 Trial For Novel Stem Cell Mobilization Treatment
6/16/2014 12:01:05 PM
JERUSALEM--(BUSINESS WIRE)--BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received approval from the Israeli Ministry of Health to commence a Phase 1 trial for BL-8040, a novel treatment for the mobilization of stem cells from the bone marrow to the peripheral blood circulation. The study is expected to commence during the third quarter of 2014 at Hadassah Medical Center in Jerusalem.
Help employers find you! Check out all the jobs and post your resume.
comments powered by